Developer docs
API playgroundTry for free, no card

Search company profiles

Triomics

Full company profile

uuid0000isy

Namestring
Triomics
Legal namestring
Triomics Inc.
Websiteurl
triomics.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Triomics is a privately held, New York–headquartered generative AI company founded in 2021 by Sarim Khan (CEO) and Hrituraj Singh (CTO) that builds oncology-specific AI infrastructure to convert unstructured cancer records into structured, cited, auditable intelligence. Its core technology, OncoLLM, is a proprietary constellation of eight specialized large language models ranging from 3B to 72B parameters, paired with the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG inputs from Epic, OncoEMR, iKnowMed, and Cerner into LLM-ready data, enabling patient-level reasoning across the full longitudinal record (notes, pathology, imaging, molecular, scanned faxes). Triomics packages this platform as three workflow modules: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for cancer registry curation and structured data abstraction against NAACCR, CoC, and QOPI dictionaries. The platform's accuracy has been peer-reviewed in Nature Digital Medicine and presented at the ASCO 2025 Annual Meeting and Quality Care Symposium, with reported outcomes of 95% extraction and trial match accuracy, a 40% increase in trial matches, more than 30% increase in enrollments, and a 67% reduction in manual chart review time.

The company sells primarily through enterprise SaaS contracts with cancer centers and life-sciences organizations, supplemented by forward-deployed implementation and professional services, with custom quote-based pricing, no public list prices, and 30-minute demo sessions gated by BAAs for customer data. It serves three primary customer segments: NCI-designated academic cancer centers (4 of the top 10 U.S. cancer centers and 10+ NCI-designated centers are deployed, including MSK, MD Anderson, Yale/Smilow, Mount Sinai, and IU Health), large community oncology networks (Texas Oncology), and pharmaceutical/life-sciences sponsors (Eli Lilly, with deployment at investigator sites for enrollment, feasibility, and protocol design). The company is venture-backed, with a $15M Series A in May 2024 and a $22M Series B in May 2026 led by Battery Ventures, bringing total disclosed funding to over $36M; reported metrics include a 10x year-over-year increase in ARR and a 4x expansion of enterprise customers alongside platform-wide processing of 1,000,000+ medical records and screening of 65,000+ patients for trials per month.

Short descriptiontext

Triomics builds OncoLLM, an oncology-tuned generative AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for NCI-designated cancer centers, community oncology practices, and pharmaceutical sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial matching, oncology AI software, cancer registry abstraction, healthcare LLM platform, patient cohort identification
Industry4 codes
PRIMARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAHAI
Clinical & Claims Data Integration for Population Health (payer-provider data fusion)
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAIAL
Data Access, Sharing & Marketplace Platforms (incl. TEFCA/QHIN enablement)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
NAICS code3 codes
  • Computer Systems Design and Related Services54151
  • Software Publishers5132
  • Computer Systems Design Services541512
SIC code3 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Computer Integrated Systems Design7373
  • Services-Prepackaged Software7372
Product category
Oncology clinical AI software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise SaaS subscriptions (implied)
TypeSubscription Recurring
Description

Triomics deploys its PRISM, Symphony, and Harmony platforms into cancer centers and life-sciences organizations under multi-year contracts. TechCrunch reports a 10-fold increase in annualized recurring revenue over the prior year, indicating a recurring SaaS revenue model. Customer contracts are site-governed under HIPAA, IRB, and CTA requirements.

triomics.com
2Life sciences / sponsor services
TypeManaged Services
Description

Sponsor-facing capabilities (accelerated enrollment, screening throughput visibility, precise feasibility, trial design optimization) packaged for pharma/biotech sponsors using Triomics deployments at investigator sites; outputs governed by site-approved data-sharing.

triomics.com
3Deployment and implementation services (implied)
TypeProfessional Services
Description

Forward-deployed engineering teams are explicitly being expanded with the Series B, supporting deployment, integration, and ongoing implementation for enterprise customers — indicative of professional services revenue bundled with the platform.

triomics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Quote-based enterprise contracts for PRISM, Symphony, and Harmony deployments
ModelOther
Notes

Pricing not publicly disclosed; demos offered via 30-minute working session with the team (synthetic-data sandbox or BAA-uploaded de-identified data).

triomics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1PRISM
Description

AI-powered clinical trial matching platform that screens every upcoming patient against every active trial and produces cited, prioritized worklists (Patient Records Interpretation for Semantic clinical trial Matching system).

triomics.com
+3 more records
Core offering1 text field

Triomics builds an oncology-specialized generative AI platform that automates clinical trial matching, pre-visit charting, and cancer registry abstraction for cancer centers, oncology practices, and life sciences sponsors. The platform combines a proprietary suite of fine-tuned large language models (OncoLLM) with a unified EHR ingestion pipeline (OncoIndexer) to surface eligible patients and streamline oncology workflows. It is sold as enterprise software to provider organizations and as solutions to pharma sponsors for patient identification and cohort analytics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 95% accuracy in PRISM patient-to-trial matching
+7 more records
Product overview1 text field

Triomics offers a single unified AI platform — OncoLLM — packaged as a constellation of eight specialized large language models (3B to 72B parameters) that reason at the patient level across the full longitudinal oncology record, with three named workflow modules built on top: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for registry-ready structured data abstraction. The platform is delivered through two solution suites — a Cancer Centers suite for providers and a Life Sciences suite for sponsors — supported by the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG data from EMR systems including Epic, OncoEMR, iKnowMed, and Cerner.

Product and service7 records
1OncoLLM
CategoryAI platform / foundation model
Description

Oncology-specialized large language model suite comprising eight fine-tuned models that power Triomics' clinical workflows; used internally as the AI foundation for all customer-facing products.

2OncoIndexer
CategoryData pipeline / platform component
Description

Data ingestion and normalization pipeline that processes structured and unstructured EHR and oncology data and feeds it into OncoLLM and downstream products.

3PRISM
CategoryClinical trial matching software
Description

Clinical trial matching and eligibility-screening product that identifies oncology patients eligible for relevant trials using OncoLLM; sold to cancer centers, practices, and life sciences sponsors.

4Symphony
CategoryClinical workflow automation
Description

Pre-charting and visit-preparation product that uses OncoLLM to assemble oncology visit notes and documentation ahead of patient appointments.

5Harmony
CategoryCancer registry abstraction software
Description

Cancer registry abstraction and reporting product that uses OncoLLM to extract structured registry data from oncology records for cancer program reporting.

6Cancer Centers Platform
CategoryOncology provider software suite
Description

Provider-facing solution bundle of Triomics' products (PRISM, Symphony, Harmony) sold to cancer centers and oncology practices for trial matching, pre-charting, and registry abstraction.

7Life Sciences Solutions
CategoryPharma / life sciences analytics software
Description

Sponsor-facing solution offering patient identification, cohort analytics, and real-world oncology data generation for pharmaceutical, biotech, and clinical research customers.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCore Research PartnerTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-05
Description

Sponsor-funded hybrid effectiveness-implementation study to evaluate Triomics PRISM with IU Health Oncology; Dr. Jiang Bian leads technical audit and Dr. David Haggstrom leads implementation evaluation.

Strategic tierCore Research PartnerTypeStrategic or Co-development PartnerAnnounced on2026-02-05
Description

Triomics PRISM is being evaluated across two IU Health oncology satellite sites in a hybrid effectiveness-implementation study with Regenstrief and Eli Lilly.

Strategic tierCore Research Sponsor PartnerTypeStrategic or Co-development PartnerAnnounced on2026-02-05
Description

Sponsor of the Triomics PRISM hybrid effectiveness-implementation study with IU Health and Regenstrief; collaboration funded to evaluate AI-enabled clinical trial screening in real oncology workflows.

Strategic tierFlagship Customer / Flagship PartnerTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Launched PRISM (powered by Triomics' OncoLLM) for systemwide clinical trial matching across the Mount Sinai Health System; first NCI-designated Comprehensive Cancer Center in NYC to deploy oncology-specific AI for systemwide matching.

Strategic tierFlagship Customer / Flagship PartnerTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Expanded use of Triomics' AI-powered clinical-trial screening at Yale Cancer Center and Smilow Cancer Hospital in Connecticut; PRISM pre-screens 100% of patient visits against all active trials.

Strategic tierCore Technology PartnerTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Savista partners with Triomics to launch the industry's first automated, full-stack cancer registry solution, combining Savista's registry expertise with Triomics' OncoLLM-based abstraction.

Strategic tierFlagship Customer / Flagship PartnerTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Triomics announced a collaboration with MSK to deploy its AI-powered clinical trial matching system, including expansion across MSK's clinical trial portfolio and decentralized trials in satellite clinics.

Strategic tierCore Ehr Integration PartnerTypeTechnology or Integration
Description

Native integration with Epic; PRISM is approved on the Epic App Marketplace. Outputs land in Epic in-baskets, worklists, and EHR notes.

9OncoEMR
Strategic tierCore Oncology Ehr Integration PartnerTypeTechnology or Integration
Description

Native integration with OncoEMR alongside Epic and iKnowMed.

triomics.com
10iKnowMed
Strategic tierCore Oncology Ehr Integration PartnerTypeTechnology or Integration
Description

Native integration with iKnowMed (used by community oncology practices such as US Oncology Network).

triomics.com
11Cerner
Strategic tierCore Ehr Integration PartnerTypeTechnology or Integration
Description

Listed alongside Epic, OncoEMR as a native EMR integration supported by Triomics PRISM.

triomics.com
Strategic tierFlagship Community Oncology Partner And Investor AffiliateTypeStrategic or Co-development Partner
Description

Triomics is working with Texas Oncology, one of the nation's largest community oncology practices; Precision Health Informatics (a Texas Oncology subsidiary) is both a strategic investor in the Series B and a customer channel.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Deep 6 AI
TypeDirect peer
Description

AI-driven patient recruitment and clinical-trial matching platform that mines EHR data to identify eligible patients. Directly comparable to Triomics PRISM in target use case (patient-to-trial matching), customer base (health systems and sponsors), and underlying technology (EHR-mining AI).

2Mendel
TypeDirect peer
Description

Generative-AI platform for structuring unstructured clinical text and surfacing patients for clinical trials and research cohorts. Closely comparable to Triomics OncoLLM in core technology and to PRISM in trial matching, with overlapping buyers in life sciences and academic medical centers.

TypeDirect peer
Description

AI-powered oncology clinical trial matching and enrollment service for cancer patients and sponsors. Directly comparable to Triomics PRISM in oncology-specific trial matching, with overlap in pharma-sponsor go-to-market.

TypeDirect peer
Description

Oncology-specific clinical trial search and matching platform used by cancer centers and sponsors. Comparable to PRISM in oncology trial matching and to Triomics' cancer-center go-to-market.

TypeBroad incumbent
Description

Roche-owned oncology-specific EHR, real-world data, and AI platform for cancer centers and life-sciences sponsors. A larger incumbent in the same oncology AI/data space that Triomics addresses with OncoLLM, PRISM, and Harmony.

6Tempus
TypeBroad incumbent
Description

Public precision-medicine and AI company combining molecular profiling, oncology data, and clinical AI for providers and pharma. Broad incumbent competing with Triomics across oncology data, AI insights, and pharma services.

TypeBroad incumbent
Description

Oncology real-world data and AI SaaS for providers, payers, and life-sciences sponsors. Comparable to Triomics in oncology data abstraction (Harmony) and life-sciences offerings.

TypeBroad incumbent
Description

Oncology real-world evidence and decision-support platform for providers and pharma. Comparable to Triomics in oncology-specific data curation and life-sciences analytics.

TypeBroad incumbent
Description

Global clinical research and data powerhouse with AI-enabled trial matching and feasibility offerings (e.g., E360). Broad incumbent competing with Triomics' life-sciences/sponsor side and with the scale to bundle trial-matching into enterprise contracts.

TypeEmerging player
Description

AI platform for real-world evidence generation from EHR data, used by health systems and life sciences. Emerging peer with partial overlap in AI-driven oncology insights and life-sciences evidence generation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Triomics

Oncology clinical AI softwaretriomics.com

Triomics builds OncoLLM, an oncology-tuned generative AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for NCI-designated cancer centers, community oncology practices, and pharmaceutical sponsors.

What Triomics does

Triomics is a privately held, New York–headquartered generative AI company founded in 2021 by Sarim Khan (CEO) and Hrituraj Singh (CTO) that builds oncology-specific AI infrastructure to convert unstructured cancer records into structured, cited, auditable intelligence. Its core technology, OncoLLM, is a proprietary constellation of eight specialized large language models ranging from 3B to 72B parameters, paired with the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG inputs from Epic, OncoEMR, iKnowMed, and Cerner into LLM-ready data, enabling patient-level reasoning across the full longitudinal record (notes, pathology, imaging, molecular, scanned faxes). Triomics packages this platform as three workflow modules: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for cancer registry curation and structured data abstraction against NAACCR, CoC, and QOPI dictionaries. The platform's accuracy has been peer-reviewed in Nature Digital Medicine and presented at the ASCO 2025 Annual Meeting and Quality Care Symposium, with reported outcomes of 95% extraction and trial match accuracy, a 40% increase in trial matches, more than 30% increase in enrollments, and a 67% reduction in manual chart review time.

The company sells primarily through enterprise SaaS contracts with cancer centers and life-sciences organizations, supplemented by forward-deployed implementation and professional services, with custom quote-based pricing, no public list prices, and 30-minute demo sessions gated by BAAs for customer data. It serves three primary customer segments: NCI-designated academic cancer centers (4 of the top 10 U.S. cancer centers and 10+ NCI-designated centers are deployed, including MSK, MD Anderson, Yale/Smilow, Mount Sinai, and IU Health), large community oncology networks (Texas Oncology), and pharmaceutical/life-sciences sponsors (Eli Lilly, with deployment at investigator sites for enrollment, feasibility, and protocol design). The company is venture-backed, with a $15M Series A in May 2024 and a $22M Series B in May 2026 led by Battery Ventures, bringing total disclosed funding to over $36M; reported metrics include a 10x year-over-year increase in ARR and a 4x expansion of enterprise customers alongside platform-wide processing of 1,000,000+ medical records and screening of 65,000+ patients for trials per month.

Triomics firmographics

Firmographics
Name
Triomics
Legal name
Triomics Inc.
Website
https://triomics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Triomics builds OncoLLM, an oncology-tuned generative AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for NCI-designated cancer centers, community oncology practices, and pharmaceutical sponsors.
Ownership category
akta.pro rank

Triomics industry classification

Industry
Product category
Oncology clinical AI software
NAICS
Computer Systems Design and Related Services (54151), Software Publishers (5132), Computer Systems Design Services (541512)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Computer Integrated Systems Design (7373), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAHAI
Clinical & Claims Data Integration for Population Health (payer-provider data fusion)
Healthcare & Life Sciences/Digital Health & Health IT/Population Health Management & Value-Based Care Analytics
SECONDARYHLACAIAL
Data Access, Sharing & Marketplace Platforms (incl. TEFCA/QHIN enablement)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance

Keywords

  • Clinical trial matching
  • Oncology AI software
  • Cancer registry abstraction
  • Healthcare LLM platform
  • Patient cohort identification

Where Triomics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Triomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Enterprise SaaS subscriptions (implied): Triomics deploys its PRISM, Symphony, and Harmony platforms into cancer centers and life-sciences organizations under multi-year contracts. TechCrunch reports a 10-fold increase in annualized recurring revenue over the prior year, indicating a recurring SaaS revenue model. Customer contracts are site-governed under HIPAA, IRB, and CTA requirements.
  2. Life sciences / sponsor services: Sponsor-facing capabilities (accelerated enrollment, screening throughput visibility, precise feasibility, trial design optimization) packaged for pharma/biotech sponsors using Triomics deployments at investigator sites; outputs governed by site-approved data-sharing.
  3. Deployment and implementation services (implied): Forward-deployed engineering teams are explicitly being expanded with the Series B, supporting deployment, integration, and ongoing implementation for enterprise customers — indicative of professional services revenue bundled with the platform.

Pricing tiers

ModelBillingPrice
Other—Quote-based enterprise contracts for PRISM, Symphony, and Harmony deployments

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Triomics product offering

Product offering

Core offering

Triomics builds an oncology-specialized generative AI platform that automates clinical trial matching, pre-visit charting, and cancer registry abstraction for cancer centers, oncology practices, and life sciences sponsors. The platform combines a proprietary suite of fine-tuned large language models (OncoLLM) with a unified EHR ingestion pipeline (OncoIndexer) to surface eligible patients and streamline oncology workflows. It is sold as enterprise software to provider organizations and as solutions to pharma sponsors for patient identification and cohort analytics.

Product overview

Triomics offers a single unified AI platform — OncoLLM — packaged as a constellation of eight specialized large language models (3B to 72B parameters) that reason at the patient level across the full longitudinal oncology record, with three named workflow modules built on top: PRISM for clinical trial matching, Symphony for visit preparation and pre-charting, and Harmony for registry-ready structured data abstraction. The platform is delivered through two solution suites — a Cancer Centers suite for providers and a Life Sciences suite for sponsors — supported by the OncoIndexer ingestion pipeline that normalizes HL7, FHIR, CCDA, XML, PDF, TIFF, and JPEG data from EMR systems including Epic, OncoEMR, iKnowMed, and Cerner.

Differentiator

Problem solved

Functional benefit

Brands

  • PRISM: AI-powered clinical trial matching platform that screens every upcoming patient against every active trial and produces cited, prioritized worklists (Patient Records Interpretation for Semantic clinical trial Matching system).
  • Symphony
  • Harmony
  • OncoLLM

Products and services

  • OncoLLM Oncology-specialized large language model suite comprising eight fine-tuned models that power Triomics' clinical workflows; used internally as the AI foundation for all customer-facing products.
  • OncoIndexer Data ingestion and normalization pipeline that processes structured and unstructured EHR and oncology data and feeds it into OncoLLM and downstream products.
  • PRISM Clinical trial matching and eligibility-screening product that identifies oncology patients eligible for relevant trials using OncoLLM; sold to cancer centers, practices, and life sciences sponsors.
  • Symphony Pre-charting and visit-preparation product that uses OncoLLM to assemble oncology visit notes and documentation ahead of patient appointments.
  • Harmony Cancer registry abstraction and reporting product that uses OncoLLM to extract structured registry data from oncology records for cancer program reporting.
  • Cancer Centers Platform Provider-facing solution bundle of Triomics' products (PRISM, Symphony, Harmony) sold to cancer centers and oncology practices for trial matching, pre-charting, and registry abstraction.
  • Life Sciences Solutions Sponsor-facing solution offering patient identification, cohort analytics, and real-world oncology data generation for pharmaceutical, biotech, and clinical research customers.

Quantifiable outcome

  • 95% accuracy in PRISM patient-to-trial matching
  • +7 more outcomes

Companies that use Triomics

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Triomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability10 records

Feature7 records

Triomics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core research partner, core research sponsor partner, flagship customer / flagship partner, core technology partner, core ehr integration partner, core oncology ehr integration partner and flagship community oncology partner and investor affiliate.

  • Regenstrief Institutecore research partnerImplementation/ SI/ Consulting Partner · 5 February 2026Sponsor-funded hybrid effectiveness-implementation study to evaluate Triomics PRISM with IU Health Oncology; Dr. Jiang Bian leads technical audit and Dr. David Haggstrom leads implementation evaluation.
  • IU Health Oncologycore research partnerStrategic or Co-development Partner · 5 February 2026Triomics PRISM is being evaluated across two IU Health oncology satellite sites in a hybrid effectiveness-implementation study with Regenstrief and Eli Lilly.
  • Eli Lilly and Companycore research sponsor partnerStrategic or Co-development Partner · 5 February 2026Sponsor of the Triomics PRISM hybrid effectiveness-implementation study with IU Health and Regenstrief; collaboration funded to evaluate AI-enabled clinical trial screening in real oncology workflows.
  • Mount Sinai Tisch Cancer Centerflagship customer / flagship partnerStrategic or Co-development Partner · 8 January 2026Launched PRISM (powered by Triomics' OncoLLM) for systemwide clinical trial matching across the Mount Sinai Health System; first NCI-designated Comprehensive Cancer Center in NYC to deploy oncology-specific AI for systemwide matching.
  • Yale Cancer Center / Smilow Cancer Hospitalflagship customer / flagship partnerStrategic or Co-development Partner · 18 November 2025Expanded use of Triomics' AI-powered clinical-trial screening at Yale Cancer Center and Smilow Cancer Hospital in Connecticut; PRISM pre-screens 100% of patient visits against all active trials.
  • Savistacore technology partnerStrategic or Co-development Partner · 4 November 2025Savista partners with Triomics to launch the industry's first automated, full-stack cancer registry solution, combining Savista's registry expertise with Triomics' OncoLLM-based abstraction.
  • Memorial Sloan Kettering Cancer Center (MSK)flagship customer / flagship partnerStrategic or Co-development Partner · 23 October 2025Triomics announced a collaboration with MSK to deploy its AI-powered clinical trial matching system, including expansion across MSK's clinical trial portfolio and decentralized trials in satellite clinics.
  • Epic Systemscore ehr integration partnerTechnology or IntegrationNative integration with Epic; PRISM is approved on the Epic App Marketplace. Outputs land in Epic in-baskets, worklists, and EHR notes.
  • OncoEMRcore oncology ehr integration partnerTechnology or IntegrationNative integration with OncoEMR alongside Epic and iKnowMed.
  • iKnowMedcore oncology ehr integration partnerTechnology or IntegrationNative integration with iKnowMed (used by community oncology practices such as US Oncology Network).
  • Cernercore ehr integration partnerTechnology or IntegrationListed alongside Epic, OncoEMR as a native EMR integration supported by Triomics PRISM.
  • Texas Oncology (Precision Health Informatics)flagship community oncology partner and investor affiliateStrategic or Co-development PartnerTriomics is working with Texas Oncology, one of the nation's largest community oncology practices; Precision Health Informatics (a Texas Oncology subsidiary) is both a strategic investor in the Series B and a customer channel.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Triomics competitors and assessment

Company assessment

Direct peers

  • Deep 6 AI: AI-driven patient recruitment and clinical-trial matching platform that mines EHR data to identify eligible patients. Directly comparable to Triomics PRISM in target use case (patient-to-trial matching), customer base (health systems and sponsors), and underlying technology (EHR-mining AI).
  • Mendel: Generative-AI platform for structuring unstructured clinical text and surfacing patients for clinical trials and research cohorts. Closely comparable to Triomics OncoLLM in core technology and to PRISM in trial matching, with overlapping buyers in life sciences and academic medical centers.
  • Massive Bio: AI-powered oncology clinical trial matching and enrollment service for cancer patients and sponsors. Directly comparable to Triomics PRISM in oncology-specific trial matching, with overlap in pharma-sponsor go-to-market.
  • Trial Library: Oncology-specific clinical trial search and matching platform used by cancer centers and sponsors. Comparable to PRISM in oncology trial matching and to Triomics' cancer-center go-to-market.

Broad incumbents

  • Flatiron Health: Roche-owned oncology-specific EHR, real-world data, and AI platform for cancer centers and life-sciences sponsors. A larger incumbent in the same oncology AI/data space that Triomics addresses with OncoLLM, PRISM, and Harmony.
  • Tempus: Public precision-medicine and AI company combining molecular profiling, oncology data, and clinical AI for providers and pharma. Broad incumbent competing with Triomics across oncology data, AI insights, and pharma services.
  • ConcertAI: Oncology real-world data and AI SaaS for providers, payers, and life-sciences sponsors. Comparable to Triomics in oncology data abstraction (Harmony) and life-sciences offerings.
  • Syapse: Oncology real-world evidence and decision-support platform for providers and pharma. Comparable to Triomics in oncology-specific data curation and life-sciences analytics.
  • IQVIA (E360 / Patient Finder): Global clinical research and data powerhouse with AI-enabled trial matching and feasibility offerings (e.g., E360). Broad incumbent competing with Triomics' life-sciences/sponsor side and with the scale to bundle trial-matching into enterprise contracts.

Emerging players

  • Atropos Health: AI platform for real-world evidence generation from EHR data, used by health systems and life sciences. Emerging peer with partial overlap in AI-driven oncology insights and life-sciences evidence generation.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Triomics social profiles

Digital presence

Triomics compliance and trust

Trust signal

Compliance5 records

Triomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Triomics leadership team

Management profile

Number of profiles

Profiles3 records

Triomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Triomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triomics

What does Triomics do?

Triomics builds an oncology-specialized generative AI platform that automates clinical trial matching, pre-visit charting, and cancer registry abstraction for cancer centers, oncology practices, and life sciences sponsors. The platform combines a proprietary suite of fine-tuned large language models (OncoLLM) with a unified EHR ingestion pipeline (OncoIndexer) to surface eligible patients and streamline oncology workflows. It is sold as enterprise software to provider organizations and as solutions to pharma sponsors for patient identification and cohort analytics.

Is Triomics a public or private company?

Triomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Triomics founded?

Triomics was founded in 2021. It employs 51 to 100 people.

Where is Triomics based?

Triomics is headquartered in New York, United States, in the North America region.

How does Triomics make money?

Three revenue lines are on record. Enterprise SaaS subscriptions (implied) is the primary driver. The others are life sciences / sponsor services and deployment and implementation services (implied).

Who are Triomics's main competitors?

Direct peers on record are Deep 6 AI, Mendel, Massive Bio and Trial Library. Broad incumbents are Flatiron Health, Tempus, ConcertAI, Syapse and IQVIA (E360 / Patient Finder). Atropos Health is listed as an emerging player.

Does Triomics have an API?

No public API is recorded for Triomics.

What industry is Triomics in?

Triomics's product category is Oncology clinical AI software. Its primary akta.pro industry code is HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 54151 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupHub.aiTriomics Secures $22M for Cancer Data AITriomics, an AI company focused on oncology, raised $22 million in Series B funding to scale its platform that helps cancer centers manage complex clinical information. The funding will support the company's growth in tackling information overload in oncology and improving patient care delivery. The investment signals continued investor interest in healthcare AI solutions.FoundersTodayTriomics raises $22M Series B to bring Oncology-Focused AI to Cancer CentersTriomics, an oncology-focused healthcare AI startup, has raised $22 million in Series B funding led by Battery Ventures, with participation from Nexus Venture Partners, Lightspeed, Y Combinator, and other investors. The company develops AI-powered software to automate clinical and administrative workflows for cancer centers, reporting its enterprise customer base has grown fourfold and annual recurring revenue has grown tenfold over the past year. The capital will be used to further develop the platform, expand commercial operations, and accelerate adoption across cancer centers and healthcare systems.HIT ConsultantTriomics Secures $22M to Automate Oncology AI Chart AbstractionOncology AI company Triomics has closed a $22M Series B financing round led by Battery Ventures, bringing its total venture funding to over $36M, with participation from Lightspeed, Nexus Venture Partners, Y Combinator, Oncology Ventures, and Precision Health Informatics. The company's AI platform automates medical chart abstraction, achieving a 67% reduction in manual review times while boosting clinical trial matches by 40% and enrollment by over 30%, according to peer-reviewed validation in Nature Digital Medicine. The funding will be used to expand AI engineering teams, accelerate health system adoption, and scale the platform across global provider and life sciences networks.Pulse 2.0Triomics: $22 Million Raised To Scale AI Infrastructure For Oncology WorkflowsTriomics, an oncology AI company, raised $22 million in Series B financing led by Battery Ventures with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, plus strategic backers Oncology Ventures and Precision Health Informatics, bringing total funding to over $36 million. The company will use the capital to accelerate adoption across health systems, oncology networks, and life sciences organizations, while expanding its AI, engineering, and forward deployed teams. Triomics processes longitudinal cancer patient records and converts unstructured clinical data into structured outputs, with published results showing users increased trial matches by 40%, trial enrollments by over 30%, and reduced chart review times by 67%.PR NewswireTrusted by Leading Cancer Centers to Solve Oncology's Information Overload, Triomics Raises $22 million to Accelerate AdoptionTriomics, an oncology AI company, raised $22 million in Series B funding led by Battery Ventures with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, bringing total funding raised to date to over $36 million. The company will use the capital to accelerate adoption of its AI platform across cancer centers, oncology networks, and life sciences organizations, and grow its AI and engineering teams. Triomics already serves major cancer centers including Memorial Sloan Kettering, MD Anderson, and Yale Cancer Center, with published results showing a 40% increase in trial matches, 67% reduction in chart review times, and over 30% increase in trial enrollments.Venture Capital Access OnlineTrusted by Leading Cancer Centers to Solve Oncology's Information Overload, Triomics Raises $22 million to Accelerate AdoptionTriomics raised $22 million in Series B financing led by Battery Ventures, bringing total funding to over $36 million. The company will use the capital to accelerate adoption across cancer centers and expand its AI platform for clinical workflows and trial matching.VC News DailyTriomics Inks $22M Series B FundingTriomics, an oncology AI company, raised $22 million in Series B financing led by Battery Ventures. The round brings total funding to over $36 million. The company's platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction.TechStartupsVenture Capital & Startup Funding Roundup, May 28, 2026On May 28, 2026, multiple startups raised capital, led by Anthropic's $65 billion Series H at a $965 billion valuation. Other rounds included Fonoa's $110 million tax-compliance raise, Corgi's $106 million insurance round, and Garner Health's $100 million healthcare round. The activity signals capital flowing into regulated enterprise workflows rather than pure model-building.TechStartupsAnthropic becomes the world’s most valuable AI startup, nears $1 trillion valuation and surpasses OpenAIAnthropic raised $65 billion in Series H funding, valuing it at $965 billion and surpassing OpenAI as the world's most valuable AI startup. Its annualized revenue run rate surged to $47 billion, up from $30 billion earlier this year. The company plans to compete across cybersecurity, enterprise operations, and research.TechStartupsCompany accidentally spent $500 million on Claude AI in one month after forgetting usage limitsAn enterprise client accidentally spent $500 million on Anthropic's Claude in one month after failing to set usage limits. The report cites Microsoft canceling internal Claude Code licenses and Uber burning its 2026 AI budget. Companies are now implementing usage controls and budget caps.